Codexis Inc at Jefferies Healthcare Conference Transcript
Alright. Welcome, everyone, to the Jefferies Global Healthcare Conference. I'm Matt Stanton. I'm on the Life Science Tools and diagnostics team here at Jefferies. It's my pleasure to have Codexis back with us at the conference again this year. Joining us from the company, we have President and CEO, John Nicols, John, thanks for being here.
Yes, please. Thank you.
Questions & Answers
I guess to kind of kick off with a big picture question. You have the core enzyme business and the biotherapeutics pipeline. You recently started to break out segment financial performance before unallocated corporate overhead, which I think has been well received based on investor feedback. Can you just talk about how you're thinking about balancing investment in the 2 -- on one hand, you have the Performance Enzyme business, 30%-plus EBIT margins before the corporate overhead and the biotherapeutics pipeline that's consuming cash, especially in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
